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Primary sarcomas of the sellar region are uncommon, 
although a wide variety have been reported. To date, no 
cases of primary synovial sarcoma have been described as 
occurring at this site. We report an immunohistochemi-
cally and molecular genetically confirmed primary syn-
ovial sarcoma involving the sellar/parasellar region and 
cavernous sinus in an adult male. Subtotal resection 
and radiosurgery proved to be efficacious. The spec-
trum of primary sellar region sarcomas is summarized. 
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Skull base involvement by malignant tumors is usu-ally the result of direct extension or metastatic dis-ease. Well-recognized primary sarcomas involving 
this site, particularly the sella, include chordoma, chon-
drosarcoma, osteosarcoma, and a variety of postirra-
diation tumors, mainly fibrosarcomas. Pertinent to this 
report is but a single case of soft tissue synovial sarcoma 
metastatic to the sella.1 In this case report, we describe 
the first example of primary synovial sarcoma involving 
the sella/parasellar region, as well as the cavernous sinus. 
The morphologic diagnosis of synovial sarcoma was con-
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firmed by immunohistochemistry and molecular genet-
ics, which showed the diagnostic X;18 translocation. The 
patient, an adult male, initially responded favorably to 
subtotal resection and radiosurgery but has experienced 
a recurrence.
Case Study
A 48-year-old Caucasian male presented to the neu-
rosurgical clinic with a 3-month history of right-sided 
headache and blurred vision. Neurologic and visual field 
examinations revealed mild right sixth nerve palsy, pto-
sis, and left hemianopsia. General laboratory values were 
normal, as was anterior and posterior pituitary func-
tion. A CT scan revealed a 3.5-cm irregular, contrast- 
enhancing mass involving the sella and right parasellar 
region. Punctate tumoral calcification was noted (Fig. 
1). Further, MRI evaluation better defined the mass and 
showed involvement of the right cavernous sinus. Right 
optic nerve and chiasmal compression was also noted, 
as was narrowing (up to 60%) of the cavernous carotid 
artery throughout its course (Fig. 2A–C). Nonetheless, 
an MR angiogram showed normal blood flow. A right 
pterional craniotomy with subtotal (90%) resection of 
the mass was performed to decompress the optic nerve 
and obtain a diagnosis. The procedure was performed 
without complication.
A diagnosis of synovial sarcoma was made (see 
below). Because synovial sarcomas are often metastatic, 
an extensive radiographic workup was conducted; no 
other lesions were identified. Given the aggressive nature 
of the tumor, a more radical excision was undertaken 
after balloon test occlusion of the right carotid artery. 
Although no cross-filling occurred, monitoring over the 
20-minute period of occlusion revealed no neurologic 
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effect. A right orbitozygomatic osteotomy and Dolenc 
procedure were performed.2–4 Proximal control of the 
carotid artery was achieved through exposure of the 
petrous apex. The third, fourth, and fifth cranial nerves 
were grossly invaded by tumor and could not be sal-
vaged. The adventitia of the cavernous carotid artery 
was also grossly infiltrated but was not resected because 
it had remained patent. Postoperative MRI scans showed 
only focal residual tumor on the carotid artery. Adjunc-
tive, single-dose, image-guided radiosurgery (1,800 cGy 
to the 50% isodose line; maximum dose, 3,600 cGy) 
to the residual tumor and its bed (treatment volume, 
6.3 cm3) was undertaken. With the exception of right 
ophthalmoplegia, the patient remained neurologically 
intact for 11 months, with no evidence of regrowth on 
MRI scan. Thereafter, a recurrence was noted just out-
side the original radiation field involving the skull base, 
and an exophytic retroclival extension caused compres-
sion upon the anterior pons. He continued to remain 
neurologically stable. Two weeks later, he underwent a 
subtotal tumor resection via a retrosigmoid approach to 
decompress the brainstem. The patient has since experi-
enced progressive dysphagia.
Fig. 1. Contrast-enhanced Ct reveals a right sellar and parasellar 
mass. Calcification is seen in the lesion.
Fig. 2. Axial contrast MRI shows a right sellar and parasellar mass 
(A). Coronal contrast MRI identifies optic nerve compression (B). 
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onstrated the presence of the X;18 translocation (fusion 
transcript SYT-SSX2) diagnostic of synovial sarcoma.
Discussion
Synovial sarcoma is an uncommon soft tissue tumor, 
accounting for 5%–10% of malignant examples. Young 
adults are primarily affected, with a mean age of 30 
years. Seventy-five percent occur near large joints, mainly 
of the lower extremities. Most of the remainder involve 
the trunk and the head and neck region with equal 
frequency,4 primarily the paravertebral and the retro- and 
parapharyngeal regions. Sinuses may also be affected.6
For the purpose of treatment planning, imaging of 
sarcomas of the cranial base requires both CT scan and 
MRI scanning. In the case of synovial sarcoma, a CT 
scan will identify calcifications in approximately one-
third of cases.7 Only a minority are bone destructive. 
In soft tissue lesions, MRI shows variation in intensity 
and enhancement, as well as frequent septation.8 Most 
tumors are relatively iso- or hypointense compared to 
muscle and iso- or slightly hyperintense compared to fat 
and, in cystic areas, show a high fluid signal.9 If resec-
tion of the carotid artery is considered, angiography 
with balloon test occlusion should also be performed, 
which typically shows prominent vascularity.
Confirming the diagnosis of synovial sarcoma relies 
upon histologic and immunochemical features,10,11 and 
in some cases, molecular genetic analysis, as well.5 Three 
histologic patterns are recognized: the classic biphasic 
form with distinct epithelial and spindle cell compo-
nents, and monophasic tumors of fibrous or epithelial 
type. The former occur with equal frequency, whereas 
the latter is rare. Our tumor is a biphasic example.
The growth rate of synovial sarcomas is often slow, 
belies their degree of malignancy, and precludes a 
timely diagnosis. The tumors are variably aggressive. 
Five-year survival rates cited often range from 40% to 
Materials and Methods
The formalin-fixed, routinely processed specimen was 
cut at 5 μm and stained with hematoxylin and eosin 
(H&E), Gomori reticulin, and periodic acid-Schiff with 
and without diastase digestion. Immunohistochemistry 
(streptavidin–biotin peroxidase complex method) uti-
lized antisera directed against epithelial membrane anti-
gen (EMA; Dako, Carpinteria, CA; 1:20, E29) keratin 
(AE1–AE3; Zymed, South San Francisco, CA; 1:200), 
vimentin (Dako; 1:500, 3B4), chromogranin (Roche, 
Indianapolis, IN; 1:1000, LK2H10), S-100 protein 
(Dako; 1:800, polyclonal), glial fibrillary acidic protein 
(Dako; 1:800, polyclonal), p53 protein (Dako; 1:200, 
DO-7), and Ki-67 (MIB-1; Dako; 1:800).
RNA extraction and reverse transcriptase (RT)-PCR 
seeking synovial sarcoma fusion transcripts SYT-SSX1 
and SYT-SSX2 were performed as previously described.5
Results
The first specimen consisted of fragments, the largest 
measuring 1.3 3 0.9 3 0.7 cm, and the second, 1 cm3 
in aggregate. H&E-stained sections showed a biphasic, 
spindle- and epithelial-appearing tumor. The former 
consisted of cytologically uniform cells disposed in 
sheets and pseudopapillary arrangements in which an 
often single layer of neoplastic cells overlay a mucoid 
to fibrous, perivascular stoma (Fig. 3A). In other areas, 
sheets of tumor cells lay enmeshed in collagen (Fig. 3B). 
True glands were not seen. The spindle cell element was 
monomorphous. Few mitoses were noted (1/10 high-
power fields at 3 3 40). No necrosis was encountered. 
Immunostains showed cytoplasmic staining for keratin 
(Fig. 4A) and membrane reactivity for EMA (Fig. 4B). 
All other markers but MIB-1 (labeling index, 22%) were 
immunonegative.
Molecular genetics studies (RT-PCR analysis) dem-
A B
Fig. 3. the histologically biphasic tumor featured a pseudopapillary epithelial component (A) and sheets of monotonous spindle cells 
enmeshed in collagen (B). Hematoxylin and eosin staining; original magnification 3160 (A) and 3250 (B).
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75%.12–15 Local recurrence is frequent, and metastasis 
is common.14,16 Primary treatment of soft tissue exam-
ples involves aggressive resection with free margins.17–19 
Unfortunately, skull base tumors may not be resectable. 
This is especially true of tumors of any kind involving 
the cavernous sinus region. Since synovial sarcoma rarely 
affects the sella, little is known regarding optimal treat-
ment. One example secondarily affecting the parasellar 
area and orbit has been reported.1 It was a metastasis 
of a primary soft tissue monophasic synovial sarcoma 
of soft tissue operated on 16 months before. Treatment 
consisted of decompression of the cavernous sinus and 
radiation therapy. At 6-month follow-up, an MRI scan 
with contrast showed no tumor recurrence. In our case, 
an orbitozygomatic osteotomy combined with a Dolenc 
procedure allowed extensive bone removal and access to 
the cavernous sinus. Unfortunately, balloon test occlu-
sion showed no cross-filling. Every attempt to preserve 
a tumor-free carotid artery was made, but due to adher-
ence of residual tumor to its adventitia, a complete resec-
tion was not possible.
Adjunctive treatments may be required. Radiation and 
chemotherapy have been studied and do result in local 
control.16,19–21 However, improved survival has not been 
seen.16,20,22 Advances in radiosurgery, specifically, image-
guided robotic radiosurgery, allow for more accurate, 
aggressive treatment in the cranial base. No data are avail-
able to confirm whether this will be beneficial.
The lion’s share of sellar tumors are pituitary ade-
nomas. Their characteristic endocrine and radiographic 
abnormalities, coupled with lack of diabetes insipidus, 
distinguishes them for a wide variety of tumors affect-
ing this anatomically complex region. Mesenchymal 
tumors occurring at this site include primarily menin-
giomas23 and hemangiopericytomas.24–27 The former 
are far more often benign or atypical than malignant,28 
whereas the latter are malignant by definition, occur-
ring in low- and high-grade forms.24,25,29 A variety of 
other benign and malignant mesenchymal tumors, aris-
ing either in dura or in bone, occasionally affect the 
sellar region.30,31 These include solitary fibrous tumor,32 
fibrosarcoma,33–35 osteosarcoma,36 chondrosarcoma,37 
mesenchymal chondrosarcoma,38 leiomyosarcoma,39,40 
chordoma,41,42 rhabdomyosarcoma,43,44 and alveolar 
soft part sarcoma.45
A similar variety of sellar region sarcoma arises after 
radiotherapy, nearly always for pituitary adenoma. The 
relative and cumulative risk of their development has been 
calculated.46 The minimal therapeutic dose is approxi-
mately 3,000 cGy.47 The latency period from adenoma 
irradiation to presentation of the sarcoma varies greatly, 
ranging from as little as 2 years to as many as 40 years.48 
Most examples are fibrosarcomas intimately associated 
with residual adenoma,47,49 but osteosarcoma48,50–52 and 
even leiomyosarcoma25 have also been reported. Fatal 
tumors often vary in their rate of progression and fre-
quently recur but tend not to metastasize.
Conclusion
The spectrum of skull base sarcomas, particularly of the 
sellar region, is highly varied. Synovial sarcoma of the 
skull base is a rarely encountered entity. Most result in 
metastatic disease. This is the first reported case of syno-
vial sarcoma involving the sella and parasellar region, 
as well as the cavernous sinus. The diagnosis was con-
firmed by both immunohistochemistry and molecular 
genetic testing. In that a complete resection could not 
be accomplished, it was felt that image-guided robotic 
radiosurgery would be appropriate, although its use has 
not previously been reported.
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Fig. 4. Immunohistochemistry revealed both cytoplasmic keratin reactivity (A) and membrane staining for epithelial membrane antigen 
(B). Original magnification 3250 for A and B.
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